A Phase II Study of Estramustine, Docetaxel, and Carboplatin with Granulocyte-Colony-Stimulating Factor Support in Patients with Hormone-Refractory Prostate Carcinoma: Cancer and Leukemia Group B 99813

Cancer

Volumn 98, Issue 12, 2003, Pages 2592-2598

  Oh, William K ^a   Halabi, Susan ^b   Kelly, W Kevin ^c   Werner, Cary ^b   Godley, Paul A ^d   Vogelzang, Nicholas J ^e   Small, Eric J ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CALGB Statistical Center   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Growth factor; Hormone refractory disease; Progressive disease

Indexed keywords

ANDROGEN; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE SODIUM; GRANULOCYTE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; WARFARIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFECTION; LETHARGY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; PANCREATITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; SIDE EFFECT; STOMATITIS; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VERTIGO; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; ESTRAMUSTINE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 0344236282     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11829     Document Type: Article

References (26)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA. 2003;53:5-26.
2. De La Taille A, Vacherot F, Salomon L, et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis. 2001;4:204-212.
3. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998;160:1220-1229.
4. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
5. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
6. Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology. 2002;60:94-100; discussion 100.
7. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001;19:2509-2516.
8. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
9. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457-1465.
10. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-38.
11. Hussain M, Petrylak D, Fisher E, et al. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol. 1999;26:55-60.
12. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
13. Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer. 1998;6:462-468.
14. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res. 1995;15:2825-2828.
15. Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs. 1990;8 (Suppl 1):S91-S94.
16. Moore MR, Troner MB, DeSimone P, et al. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:541-542.
17. Merrin CE. Treatment of genitourinary tumours with cisdichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep. 1979;63:1579-1584.
18. Yagoda A, Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer. 1979;44:1553-1562.
19. Frank SJ, Amsterdam A, Kelly WK, et al. Platinum-based chemotherapy for patients with poorly differentiated hormone-refractory prostate cancers (HRPC): response and pathologic correlations [abstract]. Proc Am Soc Clin Oncol. 1995;15:232.
20. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
21. Wagstaff AJ, Ward A, Benfield P, et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs. 1989;37:162-190.
22. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol. 2001;28:10-14.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
24. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
25. Calvert H, Judson I, van der Vijgh WJ. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv. 1993;17:189-217.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.